The new antibiotic tetrahydrokalafungin was produced by the transformants of kalafungin producing S. tanashiensis and kalafungin-nonproducing mutants carrying the recombinant plasmid pKU523. This plasmid consists of pKU501 (J. Antibiotics 44: 995-1005, 1991) which contains the gene cluster for kalafungin biosynthesis, and additional 5 kb stability region of SCP2*.
The benzoisochromanequinone antibiotic kalafungin produced by Streptomyces tanashiensis strain Kala1* is biosynthesized from eight acetate units via a hypothetical intermediate "polyketide"2'3).
In the study of kalafungin biosynthesis in this strain, we isolated kalafungin-nonproducing mutants and classified them into seven different phenotypes {kail to VII) corresponding to the observed effects on kalafungin biosynthesis4). Recently, the plasmid pKU501 which contains a 28kb DNA fragment was cloned from the genomic library of the parent strain by colony hybridization using the polyketide synthase genes actl and III for actinorhodin biosynthesis from Streptomyces coelicolor A3(2) as probes5). In complementation experiment with the nonproducing-mutants using subclones derived from pKU501, seven genes (kail to VII) for kalafungin biosynthesis were identified5) ( Fig. 1) . However* the mutations kal-4, 9 and 10 (regulatory mutants) and kal-l, 12 and 13 (these were considered to include at least two mutations) were not complemented by the subclones. Since pKU501 was barely able to replicate in Streptomyces sp., we modified pKU501to allow its stable replication in Streptomyces sp. In this paper, we describe the modification of pKU501 and the production and structure determination of the new compoundtetrahydrokalafungin produced by transformants carrying the recombinant plasmid pKU523.
Materials and Methods Bacterial Strains and Plasmids
The kalafungin producer S. tanashiensis strain Kala and kalafungin-nonproducing mutants (kal)4) were used in this study. The restriction-reduced mutant S. tanashiensis R3-56) was used for modification of a plasmid before transformation of S. tanashiensis derivatives. S. tanashiensis was transformed as described previously6). Packaging of DNAinto the X head, infection of Escherichia coli JM108 and selection of transductants were done as described previously5). The transformants of S. tanashiensis and transductants of E. coli were stored as mycelial suspensions (4ml) containing 50% (v/v) glycerol after growing in Trypticase Soy Broth (TSB) (10 ml) supplemented with 5 //g per ml of thiostrepton at 30°C for 16hours. YMSagar7) and its liquid medium (without agar) were used for production of antibiotics.
The recombinant plasmid pKUSOl ( Fig. 2) was isolated from S. tanashiensis genomic library using E. coli-Streptomyces bifunctional cosmid pKU205 as described previously5). Plasmid DNAwas isolated from S. tanashiensis or E. coli as described by Kieser8).
Modification of pKU501
One microgram of pKU501was digested with EcoKl and treated with alkaline phosphatase. The digested pKU501 was ligated with 5kb EcoRl stability region prepared from SCP2*'9). The ligated DNAwas packaged in X head and then introduced into E. coli JM108.
Constructed plasmid pKU523containing 5 kb stability region was confirmed by their restriction maps. (Fig. 2 )
Identification of Antibiotics Obtained in Complementation Experiments
The transformants carrying pKU523 were. streaked on YMSagar (4ml) containing 3 fig of thiostrepton per ml in a small plate and incubated at 30°C for 4days, or inoculated in of YMSliquid medium (10ml) and incubated at 30°C for 3 days. The products were extracted with ethyl acetate and then identified by silica gel thin-layer chromatography using bioautography and authentic samples of kalafungin and dihydrokalafungin as described previously5).
Isolation of a NewAntibiotic
Fifty microliters of the mycelial stock suspension of S. tanashiensis kal-l l carrying pKU523 was inoculated in a 50-ml tube containing 10 ml of YMSliquid medium supplemented with 5fig of thiostrepton perml and incubated at 30°C for 20hours on a reciprocal tube shaker to obtain a seed culture. Then l ml of the seed culture was transferred into a 500-ml Erlenmeyer flask containing 100 ml of YMSliquid medium supplemented 
Results

Introduction of Stability Region into pKU501
To allow pKU501stable replication of Streptomyces sp., the 5kb stability region of SCP2* was introduced Genetic markers are abbreviated as follows. Rep., the replication region of SCP2* of S. coelicolor A3(2); Stability, the stability region for the maintenance of plasmid SGP2*.
BamUl-Sstl fragment of stability region of SCP2* was introduced into the EcoRl site by a synthetic linker.
into pKU501, which contained the replication origin of SCP2* but no stability region5), pKU523 as shown in Fig. 2 stably replicated in E. coli JM108 and S. tanashiensis derivatives in contrast to pKU501. Furthermore, complementation of kalafungin production was observed whenthe transformants carrying pKU523were grown on YMSagar or in YMSliquid medium. However, in our previous paper5), the transformants carrying subclones derived from pKU501 produced the kalafungins only when grown on YMSagar but not iri^the liquid medium.
In complementation experiments with kalafunginnonproducing mutants, kalafungin production was not only in the mutants classified in kall^Wll (kal-2, 3, 5, 6, 8, 1 1, 15 and 16) but also in regulatory mutants (kal-4, 9 and 10) and unclassified mutants (kal-l, 12 and 13) introduction of pKU523.These results suggest that at least eight genes (kalI->VII, and regulatory genes) lie on the primary 28 kbp fragments.
Production of a NewAntibiotic Fig. 3 shows a typical time course of antibiotic production by the transformants of the kal-ll and wild-type strains carrying pKU523, and the wild-type strain. The production of antimicrobial substances by these transformants was observed after 24 hours but only after 48 hours by the wild-type strain. By the analysis of Table 1 . The molecular formula, C16H16O6was assigned from its mass spectrum [m/e (305 M+1)]. The UVspectrum of the new compound suggested the presence of /Miydrojuglon skeleton and was sifted from 348 to 520nm in an alkaline solution. The shifted spectrum was identical with that of dihydrokalafungin (Fig. 4) in alkaline solution. After the alkaline solution of the newcompound was neutralized with 2n HC1, the shifted spectrum was not reversed to the original one but remained identical with that of dihydrokalafungin in neutral solution. By TLC and bioautography, the product obtained by pH shift was identified as dihydrokalafungin. This result suggested that the structure of the new compound is related to dihydrokalafungin, and that it is easily converted to dihydrokalafungin by oxidation under alkaline conditions, confirming that it has /Miydrojuglon skeleton.
The structure elucidation was performed by a comparison of *H and 13C NMRspectra (CDC13, 400 MHz) correlated spectroscopy (COSY), the C-4a (42.8 ppm), C-lOa (51.1 ppm) carbons showed the connective with resonance of methine protons 4a-H, lOa-H at 3.24ppm, 3.23 ppm, respectively. In the^^H COSY, the methine proton lOa-H at 3.23ppm coupled with methylene protons 1-H at 4.81ppm, and 4a-H at 3.24ppm and methylene protons 4-H at 1.58, 2.33 ppm. ORDspectrum of this compound was similar to that of dihydrokalafungin, indicating the same configuration of the both compounds. Based on these data, we propose the structure shownin Fig. 4 for the newantibiotic, name tetrahydrokalafungin. 
